Literature DB >> 15198542

Solubilizing poorly soluble antimycotic agents by emulsification via a solvent-free process.

Aslihan Akkar1, Pawel Namsolleck, Michael Blaut, Rainer H Müller.   

Abstract

The purpose of this study was to formulate itraconazole and ketoconazole as oil/water emulsions for parenteral delivery by using a solvent-free homogenization process, namely SolEmuls (solubilization by emulsification) technology. The drugs were incorporated in the commercial emulsion Lipofundin MCT 20%, composed of a medium-chain triglyceride/long-chain triglyceride (MCT/LCT) oil phase (1:1) and stabilized with 1.2% lecithin. Different parameters such as drug-loading capacity, long-term physical stability, and completeness of drug dissolution were investigated. Up to 10.0 mg/mL complete drug dissolution was achieved with itraconazole; at 20 mg/mL hybrid dispersion was obtained. Itraconazole-loaded emulsions were physically stable for 9 months (data up to now). Ketoconazole showed physical instability in the Lipofundin emulsion, which was stabilized with only 1.2% lecithin. Stabilization of ketoconazole-loaded emulsions was achieved using additionally Tween 80 as steric stabilizer. Higher concentrations of ketoconazole (ie, 10.0 mg/mL concentrated ketoconazole emulsions) were also produced with additional 2.0% Tween 80. Ketoconazole-loaded emulsions, 1 mg/mL, which were stabilized with 2.0% Tween 80, were stable for a period of 6 months. It can be concluded, after formulating amphotericin B and carbamazepine with SolEmuls technology, that SolEmuls was also applicable to the antimycotic agents itraconazole and ketoconazole, yielding IV-applicable emulsions with cost-effective production technologies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15198542      PMCID: PMC2784855          DOI: 10.1208/pt050124

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  6 in total

1.  Fat emulsions for parenteral nutrition. I: Evaluation of microscopic and laser light scattering methods for the determination of the physical stability.

Authors:  R H Müller; S Heinemann
Journal:  Clin Nutr       Date:  1992-08       Impact factor: 7.324

2.  The use of commercially available lipid emulsions for the preparation of amphotericin B-lipid admixtures.

Authors:  Y Shadkhan; E Segal; A Bor; Y Gov; M Rubin; D Lichtenberg
Journal:  J Antimicrob Chemother       Date:  1997-05       Impact factor: 5.790

3.  Enhanced solubility and dissolution rate of itraconazole by a solid dispersion technique.

Authors:  J Y Jung; S D Yoo; S H Lee; K H Kim; D S Yoon; K H Lee
Journal:  Int J Pharm       Date:  1999-10-05       Impact factor: 5.875

4.  An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis.

Authors:  R Kirsh; R Goldstein; J Tarloff; D Parris; J Hook; N Hanna; P Bugelski; G Poste
Journal:  J Infect Dis       Date:  1988-11       Impact factor: 5.226

5.  Formulation of intravenous carbamazepine emulsions by SolEmuls technology.

Authors:  A Akkar; R H Müller
Journal:  Eur J Pharm Biopharm       Date:  2003-05       Impact factor: 5.571

6.  Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients.

Authors:  D Caillot; O Casasnovas; E Solary; P Chavanet; B Bonnotte; G Reny; F Entezam; J Lopez; A Bonnin; H Guy
Journal:  J Antimicrob Chemother       Date:  1993-01       Impact factor: 5.790

  6 in total
  2 in total

1.  Development of amphotericin B-loaded cubosomes through the SolEmuls technology for enhancing the oral bioavailability.

Authors:  Zhiwen Yang; Yinhe Tan; Meiwan Chen; Linghui Dian; Ziyun Shan; Xinsheng Peng; Chuanbin Wu
Journal:  AAPS PharmSciTech       Date:  2012-10-23       Impact factor: 3.246

Review 2.  Microemulsions and Nanoemulsions in Skin Drug Delivery.

Authors:  Eliana B Souto; Amanda Cano; Carlos Martins-Gomes; Tiago E Coutinho; Aleksandra Zielińska; Amélia M Silva
Journal:  Bioengineering (Basel)       Date:  2022-04-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.